Agile Thinking

Share this post

User's avatar
Agile Thinking
FDA Clears Two Biomarker Assays for Early Alzheimer's Detection
Health

FDA Clears Two Biomarker Assays for Early Alzheimer's Detection

Dr. Devaki Lindsey Berkson's avatar
Dr. Devaki Lindsey Berkson
Feb 17, 2023
∙ Paid

Share this post

User's avatar
Agile Thinking
FDA Clears Two Biomarker Assays for Early Alzheimer's Detection
Share

The FDA approved two assays that reliably measure two biomarkers of Alzheimer’s disease. It measures cerebrospinal fluid (CSF) — beta-amyloid and tau proteins.

Roche's Elecsys beta-amyloid (1-42) CSF II and Elecsys phospho-tau (181P) CSF assays are to only be used in those 55 and older who are being evaluated for cognitive difficulties.

The Elecsys AD CSF…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Dr. Devaki Lindsey Berkson
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share